These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 18549892

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Distinction between benign and malignant pheochromocytomas].
    Liu TH, Chen YJ, Wu SF, Gao J, Jiang WJ, Lu ZH, Guan J, Wei SZ, Luo YF, Cao JL, Wan JW.
    Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):198-202. PubMed ID: 15256107
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas].
    Feng C, Li HZ, Yan WG, Gao JG, Xu WF, Luo YF, Cao JL.
    Zhonghua Wai Ke Za Zhi; 2007 Dec 15; 45(24):1697-700. PubMed ID: 18476530
    [Abstract] [Full Text] [Related]

  • 6. Over-diagnosis of potential malignant behavior in MEN 2A-associated pheochromocytomas using the PASS and GAPP algorithms.
    Stenman A, Zedenius J, Juhlin CC.
    Langenbecks Arch Surg; 2018 Sep 15; 403(6):785-790. PubMed ID: 29779047
    [Abstract] [Full Text] [Related]

  • 7. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior.
    Brown HM, Komorowski RA, Wilson SD, Demeure MJ, Zhu YR.
    Cancer; 1999 Oct 15; 86(8):1583-9. PubMed ID: 10526289
    [Abstract] [Full Text] [Related]

  • 8. Differential heparanase-1 expression in malignant and benign pheochromocytomas.
    Quiros RM, Kim AW, Maxhimer J, Gattuso P, Xu X, Prinz RA.
    J Surg Res; 2002 Nov 15; 108(1):44-50. PubMed ID: 12443714
    [Abstract] [Full Text] [Related]

  • 9. Histological features, Ki-67 and Bcl-2 immunohistochemical expression and their correlation with the aggressiveness of pheochromocytomas.
    Jovanovic R, Kostadinova-Kunovska S, Bogoeva B, Spasevska L, Petrusevska G.
    Prilozi; 2012 Nov 15; 33(2):23-40. PubMed ID: 23425867
    [Abstract] [Full Text] [Related]

  • 10. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas.
    Gupta D, Shidham V, Holden J, Layfield L.
    Appl Immunohistochem Mol Morphol; 2000 Dec 15; 8(4):267-74. PubMed ID: 11127918
    [Abstract] [Full Text] [Related]

  • 11. Differential expression of human telomerase catalytic subunit mRNA by in situ hybridization in pheochromocytomas.
    Luo Z, Li J, Qin Y, Ma Y, Liang X, Xian J, Lu D, Wei M, Yang JY, Yang MQ, He Z.
    Endocr Pathol; 2006 Dec 15; 17(4):387-98. PubMed ID: 17525487
    [Abstract] [Full Text] [Related]

  • 12. [Pheochromocytomas in adrenal medulla or extra-adrenal and multiple endocrine neoplasms:a clinicopathologic analysis of 181 cases].
    Jiang CX, Zeng Z, Wang T, Liu X, Liu R, Li Y.
    Zhonghua Bing Li Xue Za Zhi; 2011 Nov 15; 40(11):762-6. PubMed ID: 22336161
    [Abstract] [Full Text] [Related]

  • 13. Malignant pheochromocytoma: new malignancy criteria.
    de Wailly P, Oragano L, Radé F, Beaulieu A, Arnault V, Levillain P, Kraimps JL.
    Langenbecks Arch Surg; 2012 Feb 15; 397(2):239-46. PubMed ID: 22069042
    [Abstract] [Full Text] [Related]

  • 14. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
    Elder EE, Xu D, Höög A, Enberg U, Hou M, Pisa P, Gruber A, Larsson C, Bäckdahl M.
    Mod Pathol; 2003 Mar 15; 16(3):246-55. PubMed ID: 12640105
    [Abstract] [Full Text] [Related]

  • 15. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
    Tatić S, Havelka M, Paunović I, Bozić V, Diklic A, Brasanac D, Janković R, Jancić-Zguricas M.
    Srp Arh Celok Lek; 2002 Jul 15; 130 Suppl 2():7-13. PubMed ID: 12584991
    [Abstract] [Full Text] [Related]

  • 16. Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas - a comparative study.
    Białas M, Okoń K, Dyduch G, Ciesielska-Milian K, Buziak M, Hubalewska-Dydejczyk A, Sobrinho-Simoes M.
    Pol J Pathol; 2013 Jun 15; 64(2):129-35. PubMed ID: 23900871
    [Abstract] [Full Text] [Related]

  • 17. Prognostic markers in pheochromocytoma.
    Clarke MR, Weyant RJ, Watson CG, Carty SE.
    Hum Pathol; 1998 May 15; 29(5):522-6. PubMed ID: 9596278
    [Abstract] [Full Text] [Related]

  • 18. The role of immunohistochemistry in histopathological diagnostics of clinically "silent" incidentally detected adrenal masses.
    Babinska A, Sworczak K, Wisniewski P, Nałecz A, Jaskiewicz K.
    Exp Clin Endocrinol Diabetes; 2008 Apr 15; 116(4):246-51. PubMed ID: 18393131
    [Abstract] [Full Text] [Related]

  • 19. Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy?
    Agarwal A, Mehrotra PK, Jain M, Gupta SK, Mishra A, Chand G, Agarwal G, Verma AK, Mishra SK, Singh U.
    World J Surg; 2010 Dec 15; 34(12):3022-8. PubMed ID: 20703467
    [Abstract] [Full Text] [Related]

  • 20. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
    Wachtel H, Hutchens T, Baraban E, Schwartz LE, Montone K, Baloch Z, LiVolsi V, Krumeich L, Fraker DL, Nathanson KL, Cohen DL, Fishbein L.
    J Clin Endocrinol Metab; 2020 Dec 01; 105(12):e4661-70. PubMed ID: 32877928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.